iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV): Price and Financial Metrics ETF


iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV): $1.29

0.01 (+0.71%)

POWR Rating

Component Grades

Trade

NA

Buy & Hold

NA

Peer

NA

BWV Stock Price Chart Interactive Chart >

Price chart for BWV

BWV Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market

Current price $1.29 52-week high $90.90
Prev. close $1.28 52-week low $0.91
Day low $1.28 Volume 35,001
Day high $1.33 Avg. volume 199,256
50-day MA $1.20 Dividend yield N/A
200-day MA $2.46

iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV) ETF Bio


The investment objective of the iPath CBOE S&P 500 BuyWrite ETN is to provide investors with exposure to the CBOE S&P 500 BuyWrite Index. The Index is designed to measure the total rate of return on a hypothetical "buy-write”, or "covered call", strategy on the S&P 500® Index. This strategy consists of a hypothetical portfolio consisting of a "long” position indexed to the S&P 500 Index and the sale of a succession of a one-month, at-the-money S&P 500® call options that are listed on the Chicago Board Options Exchange.

BWV ETF Info

Issuer
Expense Ratio %
Asset Class
Sector Large Cap Blend ETFs
Assets Under Management (AUM) N/A
Net Asset Value (NAV) $0.00
Options? No
Total Holdings N/A

BWV Top Holdings

Symbol Company % of Total
%
%
%
%
%
%
%
%
%
%

Latest BWV News From Around the Web

Below are the latest news stories about BLUE WATER VACCINES INC that investors may wish to consider to help them evaluate BWV as an investment opportunity.

Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors

CINCINNATI, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Timothy Ramdeen, seasoned public market and private equity investment leader, to its board of directors. Mr. Ramdeen has nearly a decade of experience in private equity and hedge fund investing, capital markets, and company forma

Yahoo | January 17, 2023

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

CINCINNATI, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that BWV management will present at the Biotech Showcase 2023 in San Francisco, California, happening during the 41st Annual J.P. Morgan Healthcare Conference. During the presentation, management will provide a corporate overview, recent milestones

Yahoo | January 9, 2023

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

CINCINNATI, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced its first analyst coverage since going public in February 2022 with the initial recommendations as “buy” from both Maxim Group LLC (“Maxim”) and H.C. Wainwright & Co. (“H.C. Wainwright”) at price targets of $4 and $7, respectively. Copies of the fu

Yahoo | December 12, 2022

Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate

CINCINNATI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the Company will host an online Key Opinion Leader (“KOL”) event on Wednesday, December 7, 2022 from 12 p.m. – 2 p.m. EST. To kick off the event, Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines, will provide a brief Com

Yahoo | December 6, 2022

Blue Water Vaccines (NASDAQ:BWV) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | December 3, 2022

Read More 'BWV' Stories Here

BWV Price Returns

1-mo 26.47%
3-mo 5.74%
6-mo -61.49%
1-year N/A
3-year N/A
5-year N/A
YTD 17.27%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7526 seconds.